基本信息
浏览量:3
职业迁徙
个人简介
Dr. Miller has been interested in NK cell biology, NK cell development, the acquisition of NK cell receptors and seamless translation into clinical trials throughout his entire academic career. Currently, the lab is focused on mechanisms which determine the enhanced function seen with CMV induced adaptive NK cells, facilitating immune synapses with IL-15 containing Trispecific Killer Engagers (TriKEs), IL-15 biology, NK cell killer immunoglobulin receptor (KIR) acquisition and function (NK cell education), and developing NK cell therapeutics.
Throughout his career at the University of Minnesota, he has mentored faculty and delivered hundreds of NK cells products to patients with cancer. His team has identified unique NKC2C+ NK cell repertoires exhibit a methylation signature of CD8+ T cells with properties of immune memory. Adaptive NK cells are distinctly different from canonical NK cells and signal through CD16 using a dominant CD3? signal by downregulation of FcR?R1?. Adaptive NK cells are better primed for killing, cytokine production, ADCC and exhibit unique metabolic signatures that enhance their survival. He has developed state-of-the-art functional readouts to study NK cells from the laboratory and the clinic based on high resolution testing. He was the first to report that haploidentical allogeneic human NK cells can persist and expand for up to one month after adoptive transfer. Based on these studies a significant part of his effort is trying to understand how to exploit NK cells for therapeutic purposes against infection and cancer and how to improve outcomes from allogeneic hematopoietic cell transplantation.
Clinically, he has developed first-in-human trials using allogeneic donor NK cells, rhIL-15, IL-15/IL-15R?-Fc (ALT-803, now called N-803), an NK cell TriKE that engages NK cells and AML targets that costimulates NK cells with an IL-15 linker. Dr. Miller's experience and translational expertise has supported a transition from individual related donor NK cell products to induced pluripotent stem cell (iPSC) derived NK cells. Advantages of using this off-the-shelf platform include the flexibility of multiple gene edits, immediate cryopreserved product availability, multi-doing strategies and combinatorial therapy with targeted agents to enhance NK cell function.
Dr. Miller is devoted to team science and mentoring. He has supervised > 400 NK cell products and sponsored >10 INDs and his team has studied >4000 transplant patients. Dr. Miller's experience, NIH grants and translational expertise provides a rich environment for training.
Throughout his career at the University of Minnesota, he has mentored faculty and delivered hundreds of NK cells products to patients with cancer. His team has identified unique NKC2C+ NK cell repertoires exhibit a methylation signature of CD8+ T cells with properties of immune memory. Adaptive NK cells are distinctly different from canonical NK cells and signal through CD16 using a dominant CD3? signal by downregulation of FcR?R1?. Adaptive NK cells are better primed for killing, cytokine production, ADCC and exhibit unique metabolic signatures that enhance their survival. He has developed state-of-the-art functional readouts to study NK cells from the laboratory and the clinic based on high resolution testing. He was the first to report that haploidentical allogeneic human NK cells can persist and expand for up to one month after adoptive transfer. Based on these studies a significant part of his effort is trying to understand how to exploit NK cells for therapeutic purposes against infection and cancer and how to improve outcomes from allogeneic hematopoietic cell transplantation.
Clinically, he has developed first-in-human trials using allogeneic donor NK cells, rhIL-15, IL-15/IL-15R?-Fc (ALT-803, now called N-803), an NK cell TriKE that engages NK cells and AML targets that costimulates NK cells with an IL-15 linker. Dr. Miller's experience and translational expertise has supported a transition from individual related donor NK cell products to induced pluripotent stem cell (iPSC) derived NK cells. Advantages of using this off-the-shelf platform include the flexibility of multiple gene edits, immediate cryopreserved product availability, multi-doing strategies and combinatorial therapy with targeted agents to enhance NK cell function.
Dr. Miller is devoted to team science and mentoring. He has supervised > 400 NK cell products and sponsored >10 INDs and his team has studied >4000 transplant patients. Dr. Miller's experience, NIH grants and translational expertise provides a rich environment for training.
研究兴趣
论文共 853 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nicholas A. Zorko, Mary E. Shackelford, Asha Bozicevich, Joshua T. Walker, Peter Hinderlie, Gwen Phung, Melissa Khaw, Jacobi Rugloski,Amanda J. Russell, Yvette Soignier, Laura Kotz, Laura Bendzick,Justin H. Hwang,Emmanuel S. Antonarakis,Martin Felices,Jeffrey S. Miller
Journal of clinical oncologyno. 4_suppl (2024): 155-155
Carly D. Miller,John R. Lozada,Nicholas A. Zorko,Andrew Elliott,Allison Makovec,Milan Radovich,Elisabeth I. Heath,Neeraj Agarwal,Rana R. Mckay,Rohan Garje,Bruno R. Bastos,Dave S.B. Hoon,Jacob J. Orme,Oliver Sartor,Ari VanderWalde,Chadi Nabhan,George Sledge,Eugene Shenderov,Scott M. Dehm,Emil Lou,Jeffrey S. Miller,Justin H. Hwang,Emmanuel S. Antonarakis
crossref(2024)
Carly D Miller,John R Lozada,Nicholas A Zorko,Andrew Elliott,Allison Makovec,Milan Radovich,Elisabeth I Heath,Neeraj Agarwal,Rana R Mckay,Rohan Garje,Bruno R Bastos,Dave S B Hoon,Jacob J Orme,Oliver Sartor,Ari VanderWalde,Chadi Nabhan,George Sledge,Eugene Shenderov,Scott M Dehm,Emil Lou,Jeffrey S Miller,Justin H Hwang,Emmanuel S Antonarakis
Cancer research communicationsno. 5 (2024): 1369-1379
Carly D. Miller,John R. Lozada,Nicholas A. Zorko,Andrew Elliott,Allison Makovec,Milan Radovich,Elisabeth I. Heath,Neeraj Agarwal,Rana R. Mckay,Rohan Garje,Bruno R. Bastos,Dave S.B. Hoon,Jacob J. Orme,Oliver Sartor,Ari VanderWalde,Chadi Nabhan,George Sledge,Eugene Shenderov,Scott M. Dehm,Emil Lou,Jeffrey S. Miller,Justin H. Hwang,Emmanuel S. Antonarakis
crossref(2024)
Blood advancesno. 3 (2024): 581-590
Ryotaro Nakamura,Corinna La Rosa,Dongyun Yang,Joshua A. Hill,Armin Rashidi,Hannah Choe,Qiao Zhou,Chetan Raj Lingaraju,Teodora Kaltcheva,Jeffrey Longmate,Jennifer Drake,Cynthia Slape,Lupe Duarte, Monzr M. Al Malki,Vinod A. Pullarkat,Ahmed Aribi,Steven Devine,Michael R. Verneris,Jeffrey S. Miller,Stephen J. Forman
Haematologicano. 6 (2024): 1994-1999
Jenna K Dick,Jules A Sangala,Venkatramana D Krishna,Aaron Khaimraj, Lydia Hamel, Spencer M Erickson,Dustin Hicks, Yvette Soigner,Laura E Covill, Alexander Johnson,Michael J Ehrhardt,Keenan Ernste,Petter Brodin,Richard A Koup,Alka Khaitan,Carly Baehr, Beth K Thielen,Christine M Henzler, Caleb Skipper,Jeffrey S Miller,Yenan T Bryceson,Jianming Wu,Chandy C John,Angela Panoskaltsis-Mortari, Alberto Orioles,Marie E Steiner,Maxim C-J Cheeran,Marco Pravetoni,Geoffrey T Hart
bioRxiv : the preprint server for biology (2024)
Lucas Rebuffet,Janine E Melsen,Bertrand Escalière,Daniela Basurto-Lozada,Avinash Bhandoola,Niklas K Björkström,Yenan T Bryceson,Roberta Castriconi,Frank Cichocki,Marco Colonna,Daniel M Davis,Andreas Diefenbach,Yi Ding,Muzlifah Haniffa,Amir Horowitz,Lewis L Lanier,Karl-Johan Malmberg,Jeffrey S Miller, Lorenzo Moretta,Emilie Narni-Mancinelli,Luke A J O'Neill,Chiara Romagnani,Dylan G Ryan,Simona Sivori,Dan Sun,Constance Vagne,Eric Vivier
Nicholas A. Zorko,Allison Makovec,Andrew Elliott, Samuel Kellen,John R. Lozada,Ali T. Arafa,Martin Felices,Madison Shackelford, Pedro Barata,Yousef Zakharia,Vivek Narayan,Mark N. Stein,Kevin K. Zarrabi, Akash Patniak,Mehmet A. Bilen,Milan Radovich,George Sledge,Wafik S. El-Deiry,Elisabeth I. Heath,Dave S. B. Hoon,Chadi Nabhan,Jeffrey S. Miller,Justin H. Hwang,Emmanuel S. Antonarakis
Prostate cancer and prostatic diseases (2024)
加载更多
作者统计
#Papers: 853
#Citation: 54857
H-Index: 109
G-Index: 221
Sociability: 8
Diversity: 0
Activity: 5
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn